Indapta Therapeutics develops allogeneic Natural Killer (NK) cell therapies for treating cancer and autoimmune diseases.

EyeBio is a clinical-stage ophthalmology biotechnology company focused on developing therapies for sight-threatening eye diseases and has expanded its Series A funding to $130 million.